Ariad Pharmaceuticals has inked a deal with PDL BioPharma, trading a long-term royalty on its only marketed drug in exchange for money to develop another.
Boehringer Ingelheim has agreed to hand over as much as $730 million to South Korean drugmaker Hanmi Pharmaceutical in exchange for the rights to a midstage treatment for lung cancer, betting the drug can stand out in a crowded field.
For the second quarter Eli Lilly on a July 23 earnings call heard John Lechleiter, chairman, president and CEO, and his team provided upbeat talk about opportunities in Japan. But there was also some of the same comments heard from Johnson & Johnson, Abbott and Novartis on China's slowdown.
Shares of Vitae Pharmaceuticals dropped 5% this morning after the biotech reported that Boehringer Ingelheim had decided to dump its collaboration on a new BACE program for Alzheimer's.
Roche is terminating its collaboration with Molecular Partners, nixing an oncology partnership worth up to $1 billion as it reshuffles its pipeline.
Melbourne, Australia-based Adherium has pulled off a major pharma partnership just ahead of a proposed listing on the Australian Stock Exchange. It expects to list on Aug. 26, raising up to $35 million and at least $20 million. A new deal that the smart inhaler player just disclosed with AstraZeneca can only enhance its public market prospects.
Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University developed bedside data-acquisition software as part of its infant apnea prevention program. Now, it's spun off the technology into a new startup known as MediCollector.
A thwarted challenge from an activist investor to block the $8 billion merger of Samsung C&T and Cheil Industries last week has set the stage for family-controlled Samsung Electronics and related units to focus on boosting already rapid growth at Samsung BioLogics and Samsung Bioepis, the Korea Herald reports.
A report commissioned by the United Kingdom government has found data to corroborate a widely held belief: R&D collaborations with British universities are expensive. Yet with such institutions performing world-class science--and tax breaks and funding schemes offsetting the upfront costs--Big Pharma is lining up to strike deals. Just ask Pfizer.
Calgary-based Resverlogix said it has closed a deal to license greater China rights to clinical stage cardiovascular drug RVX-208 to China's Shenzhen Hepalink Pharmaceutical, putting its future on an known candidate now billed as a new treatment for atherosclerosis.